In addition, a phase 2b controlled trial is currently underway for the use of Pegasofermin—FGF-21 recombinant analogue for patients with histo-pathologically confirmed non-alcoholic steatohepatitis (NASH) and liver fibrosis. Here, FGF21 is linked to Hepatic fibrosis.